CN103360302B - 阿维莫泮的纯化方法 - Google Patents
阿维莫泮的纯化方法 Download PDFInfo
- Publication number
- CN103360302B CN103360302B CN201210089045.1A CN201210089045A CN103360302B CN 103360302 B CN103360302 B CN 103360302B CN 201210089045 A CN201210089045 A CN 201210089045A CN 103360302 B CN103360302 B CN 103360302B
- Authority
- CN
- China
- Prior art keywords
- alvimopan
- ethanol
- crude product
- volume
- ratio
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 229960004516 alvimopan Drugs 0.000 title claims abstract description 86
- UPNUIXSCZBYVBB-JVFUWBCBSA-N alvimopan Chemical compound C([C@@H](CN1C[C@@H]([C@](CC1)(C)C=1C=C(O)C=CC=1)C)C(=O)NCC(O)=O)C1=CC=CC=C1 UPNUIXSCZBYVBB-JVFUWBCBSA-N 0.000 title claims abstract description 84
- 238000000746 purification Methods 0.000 title claims abstract description 15
- 239000000243 solution Substances 0.000 claims abstract description 41
- 238000000034 method Methods 0.000 claims abstract description 35
- 239000012043 crude product Substances 0.000 claims abstract description 29
- 239000008346 aqueous phase Substances 0.000 claims abstract description 20
- 239000007864 aqueous solution Substances 0.000 claims abstract description 18
- 150000007529 inorganic bases Chemical class 0.000 claims abstract description 16
- 239000000284 extract Substances 0.000 claims abstract description 14
- 239000003960 organic solvent Substances 0.000 claims abstract description 13
- 239000012535 impurity Substances 0.000 claims abstract description 8
- 238000006243 chemical reaction Methods 0.000 claims abstract description 7
- 238000002425 crystallisation Methods 0.000 claims abstract description 6
- 230000008025 crystallization Effects 0.000 claims abstract description 6
- 150000003839 salts Chemical class 0.000 claims abstract description 5
- 239000013078 crystal Substances 0.000 claims abstract description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical group CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 81
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 81
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 72
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 54
- 238000002156 mixing Methods 0.000 claims description 23
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 6
- 239000003513 alkali Substances 0.000 claims description 4
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 3
- 239000011707 mineral Substances 0.000 claims description 3
- 230000001105 regulatory effect Effects 0.000 claims description 3
- 239000002994 raw material Substances 0.000 abstract description 6
- 238000004519 manufacturing process Methods 0.000 abstract description 4
- 230000000694 effects Effects 0.000 abstract description 3
- 238000003756 stirring Methods 0.000 description 26
- 239000000843 powder Substances 0.000 description 17
- 238000000967 suction filtration Methods 0.000 description 14
- 239000012065 filter cake Substances 0.000 description 12
- DKAGJZJALZXOOV-UHFFFAOYSA-N hydrate;hydrochloride Chemical compound O.Cl DKAGJZJALZXOOV-UHFFFAOYSA-N 0.000 description 12
- 239000012071 phase Substances 0.000 description 12
- 239000007787 solid Substances 0.000 description 12
- 238000012546 transfer Methods 0.000 description 12
- 239000000047 product Substances 0.000 description 11
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 8
- 238000001035 drying Methods 0.000 description 7
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 229960005181 morphine Drugs 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 102000003840 Opioid Receptors Human genes 0.000 description 3
- 108090000137 Opioid Receptors Proteins 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- -1 alvimopan isobutyl ester Chemical class 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 102000051367 mu Opioid Receptors Human genes 0.000 description 2
- 239000003401 opiate antagonist Substances 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 108020001612 μ-opioid receptors Proteins 0.000 description 2
- ZEMPKEQAKRGZGQ-AAKVHIHISA-N 2,3-bis[[(z)-12-hydroxyoctadec-9-enoyl]oxy]propyl (z)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCCC(O)C\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CC(O)CCCCCC)COC(=O)CCCCCCC\C=C/CC(O)CCCCCC ZEMPKEQAKRGZGQ-AAKVHIHISA-N 0.000 description 1
- MQZOZIODQPLFRF-SSLSWHBASA-N 2-methylpropyl 2-[[(2s)-2-benzyl-3-[(3r,4r)-4-(3-hydroxyphenyl)-3,4-dimethylpiperidin-1-yl]propanoyl]amino]acetate Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@@H](C(=O)NCC(=O)OCC(C)C)CC=2C=CC=CC=2)=CC=CC(O)=C1 MQZOZIODQPLFRF-SSLSWHBASA-N 0.000 description 1
- MQZOZIODQPLFRF-UHFFFAOYSA-N 2-methylpropyl 2-[[2-benzyl-3-[4-(3-hydroxyphenyl)-3,4-dimethylpiperidin-1-yl]propanoyl]amino]acetate Chemical compound C=1C=CC=CC=1CC(C(=O)NCC(=O)OCC(C)C)CN(CC1C)CCC1(C)C1=CC=CC(O)=C1 MQZOZIODQPLFRF-UHFFFAOYSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 239000008896 Opium Substances 0.000 description 1
- 239000000370 acceptor Substances 0.000 description 1
- NLTSCOZQKALPGZ-UHFFFAOYSA-N acetic acid;dihydrate Chemical compound O.O.CC(O)=O NLTSCOZQKALPGZ-UHFFFAOYSA-N 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000003243 intestinal obstruction Diseases 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229960001571 loperamide Drugs 0.000 description 1
- RDOIQAHITMMDAJ-UHFFFAOYSA-N loperamide Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)N(C)C)CCN(CC1)CCC1(O)C1=CC=C(Cl)C=C1 RDOIQAHITMMDAJ-UHFFFAOYSA-N 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 239000000014 opioid analgesic Substances 0.000 description 1
- 229960001027 opium Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000000452 restraining effect Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
Landscapes
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
Claims (11)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210089045.1A CN103360302B (zh) | 2012-03-29 | 2012-03-29 | 阿维莫泮的纯化方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210089045.1A CN103360302B (zh) | 2012-03-29 | 2012-03-29 | 阿维莫泮的纯化方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103360302A CN103360302A (zh) | 2013-10-23 |
CN103360302B true CN103360302B (zh) | 2015-08-26 |
Family
ID=49362656
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210089045.1A Expired - Fee Related CN103360302B (zh) | 2012-03-29 | 2012-03-29 | 阿维莫泮的纯化方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103360302B (zh) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1111239A (zh) * | 1993-12-08 | 1995-11-08 | 伊莱利利公司 | 3,4,4-三取代的派啶基-n-烷基羧酸盐类化合物的制备及中间体 |
CN101967118A (zh) * | 2010-10-14 | 2011-02-09 | 成都名阳药业有限公司 | 爱维莫潘的制备方法 |
CN102127005A (zh) * | 2011-01-05 | 2011-07-20 | 博瑞生物医药技术(苏州)有限公司 | 阿维莫潘的中间体及其合成方法 |
-
2012
- 2012-03-29 CN CN201210089045.1A patent/CN103360302B/zh not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1111239A (zh) * | 1993-12-08 | 1995-11-08 | 伊莱利利公司 | 3,4,4-三取代的派啶基-n-烷基羧酸盐类化合物的制备及中间体 |
CN101967118A (zh) * | 2010-10-14 | 2011-02-09 | 成都名阳药业有限公司 | 爱维莫潘的制备方法 |
CN102127005A (zh) * | 2011-01-05 | 2011-07-20 | 博瑞生物医药技术(苏州)有限公司 | 阿维莫潘的中间体及其合成方法 |
Also Published As
Publication number | Publication date |
---|---|
CN103360302A (zh) | 2013-10-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104974060A (zh) | 一种8-(2-羟基苯甲酰胺基)辛酸钠的制备方法 | |
CN105622609B (zh) | 一种利格列汀的制备方法 | |
CN105524044A (zh) | 曲格列汀杂质及其组合物 | |
CN102395591B (zh) | 一种合成普拉格雷的方法 | |
CN102060753B (zh) | 一种4-苯胺基哌啶类镇痛药的精制方法 | |
CN101962379A (zh) | 一种磺酰基异喹啉衍生物的精制方法 | |
CN103360302B (zh) | 阿维莫泮的纯化方法 | |
BR112012008464B1 (pt) | Processo para a fabricação de ácido 2-[(3,5-difluoro-3-metóxi-1,1-bifenil-4-il)amino] nicotínico e composto | |
CN104151249B (zh) | 美托咪定工业化拆分方法 | |
CN103980134B (zh) | 一种琥珀酸s-美托洛尔的制备方法 | |
CN101492411A (zh) | 一种改进的制备米格列奈的方法 | |
CN102633750A (zh) | 一锅法合成治疗糖尿病的药物瑞格列奈 | |
CN101412689A (zh) | 一种非班太尔的制备方法 | |
CN103360301B (zh) | 一种阿维莫泮中间体的纯化方法 | |
CN103373956A (zh) | 一种制备丁酸氯维地平的方法 | |
CN102603595A (zh) | (s)-奥拉西坦的制备方法 | |
CN101768164B (zh) | 一种高纯度的盐酸纳洛酮化合物 | |
CN102603594A (zh) | (s)-奥拉西坦的制备方法 | |
CN105646284A (zh) | 一种拉科酰胺的合成方法 | |
CN105693596A (zh) | 1-苄基-4-哌啶甲醛的制备方法 | |
CN101747343B (zh) | 一种舒巴坦匹酯的制备方法 | |
CN104650048B (zh) | 一种奥美沙坦酯缩合物的纯化方法 | |
CN104693177A (zh) | 一种埃索美拉唑钠的精制方法 | |
CN102924344A (zh) | 丙磺舒钠、丙磺舒钾的合成制备方法 | |
CN104262301B (zh) | 一种合成s-(+)-四氢呋喃-3-甲醇的方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CP03 | Change of name, title or address | ||
CP03 | Change of name, title or address |
Address after: 100871, Beijing, Haidian District Cheng Fu Road 298, founder building, 9 floor Patentee after: PEKING UNIVERSITY FOUNDER GROUP Co.,Ltd. Patentee after: PKUCARE PHARMACEUTICAL R&D CENTER Patentee after: PKU HEALTHCARE INDUSTRY Group Address before: 100871, Beijing, Haidian District, Cheng Fu Road, No. 298, Zhongguancun Fangzheng building, 5 floor Patentee before: PEKING UNIVERSITY FOUNDER GROUP Co.,Ltd. Patentee before: PKUCARE PHARMACEUTICAL R&D CENTER Patentee before: Pku Healthcare Industry Group Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20221020 Address after: 3007, Hengqin international financial center building, No. 58, Huajin street, Hengqin new area, Zhuhai, Guangdong 519031 Patentee after: New founder holdings development Co.,Ltd. Patentee after: PKUCARE PHARMACEUTICAL R&D CENTER Patentee after: Peking University Medical Management Co.,Ltd. Address before: 100871, Beijing, Haidian District Cheng Fu Road 298, founder building, 9 floor Patentee before: PEKING UNIVERSITY FOUNDER GROUP Co.,Ltd. Patentee before: PKUCARE PHARMACEUTICAL R&D CENTER Patentee before: PKU HEALTHCARE INDUSTRY Group |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150826 |